Biogen Inc. said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm. After taking Aduhelm, the patient was hospitalized and ...

Biogen Inc. BIIB -1.48% said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm. After taking Aduhelm, the patient was ...

Pharmaceutical company Biogen is investigating the death of a patient who had taken the company’s controversial Alzheimer’s drug Aduhelm, though it is not yet clear if there is any link. The ...

A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on Wednesday, a hospital spokesperson confirmed to Fox News.

Biogen expects to launch IMRALDI in Europe on October 16, 2018, which will complement its existing portfolio of anti-TNF therapies, BENEPALI™ (etanercept) and FLIXABI™ (infliximab).